BPC-157 — CAS 137525-51-0
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) supplied as a lyophilized reference material for in-vitro laboratory research. Supplied for laboratory research use only — not for human or veterinary use. Sold only to qualified buyers under our research-use covenant.
| Property | Value |
|---|---|
| CAS Number | 137525-51-0 |
| Sequence | GEPPPGKPADDAGLV |
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1419.53 g/mol |
| Vial Sizes Available | 5 mg, 10 mg, 20 mg |
| Price (USD) | 5 mg – $21 · 10 mg – $36 · 20 mg – $64 |
| Form | Lyophilized powder, sealed vial |
| Storage | −20 °C, protect from light |
| Purity (HPLC) | 99.21% by HPLC |
| Testing / Lot Reference | Lot 25081502 · CoA Date 2025-08-20 |
This Certificate of Analysis reports identity and purity for the lot referenced above. Purity is stated as percent area by RP-HPLC. See our guide to reading a CoA for what these figures do and do not tell you.
About this reference material
BPC-157 is supplied by BNM Research Peptides as a lyophilized powder reference material for in-vitro laboratory research. Each lot is supported by lot-specific analytical documentation; testing status, including whether results are independent third-party or manufacturer QC, is disclosed by lot in our public CoA Archive, and the Certificate of Analysis for the lot you receive is traceable to the vial label.
This listing states composition, molecular data, and handling conditions only. We do not publish or provide application, protocol, dosing, or administration information of any kind — see our Research Use Policy for the full terms governing all materials we supply.
Research Background
BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a peptide originally isolated from human gastric juice. Preclinical cell and animal studies have examined its interaction with the VEGFR2 (vascular endothelial growth factor receptor 2) signaling pathway, with one study reporting activation and upregulation of VEGFR2 in endothelial cell culture models (Hsieh et al., Journal of Molecular Medicine, 2017). A subsequent systematic review of the orthopaedic sports medicine literature catalogs the range of preclinical mechanistic studies published on this compound (PubMed, 2025).
The literature cited below addresses receptor pharmacology and mechanism only. It does not describe application, dosing, or administration, and is not guidance for any use of this material. See our Research Use Policy.
- Hsieh MJ, et al., "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation," Journal of Molecular Medicine (2017)
- "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," PubMed (2025)
Testing behind this lot
- How RP-HPLC purity testing works
- Mass spectrometry identity confirmation
- Heavy metals screening
- How to read a Certificate of Analysis
- This lot in the CoA archive (Lot 25081502)
- Karl Fischer water content
- Net peptide content vs fill weight
- Full quality control panel
For laboratory research use only. BPC-157 is a chemical reagent supplied exclusively for in-vitro laboratory research by qualified persons. It is not a drug, dietary supplement, food, cosmetic, or medical device, and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or veterinary use.